We are live on ! Find out more
BLRX

BioLineRX
BLRX

21 hedge funds and large institutions have $4.6M invested in BioLineRX in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

17% more funds holding

Funds holding: 18 → 21 (+3)

0.02% less ownership

Funds ownership: 0.03% → 0.01% (-0.02%)

31% less capital invested

Capital invested by funds: $6.66M → $4.6M (-$2.05M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
21
Holders Change
+3
Holders Change %
+16.67%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHP
Parkman Healthcare Partners
Connecticut
+$935K
2
Citadel Advisors
Citadel Advisors
Florida
+$108K
3
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$89.7K
4
SSA
Schonfeld Strategic Advisors
New York
+$77.6K
5
LPL Financial
LPL Financial
California
+$56.8K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$2.77M
2
KCM
Kennedy Capital Management
Missouri
-$1.14M
3
SM
Senvest Management
New York
-$543K
4
O
OrbiMed
New York
-$114K
5
Morgan Stanley
Morgan Stanley
New York
-$78.9K

BLRX Hedge Fund Activity: Q4 2020 in Review

21 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2020, worth a combined $4.6M — down 31% from $6.66M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BLRX positions and 5 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $935K. The largest seller was BVF Inc, exiting entirely with an estimated $2.77M sold.

  • 21 institutional investors held BioLineRX (BLRX) as of Q4 2020, up from 18 in Q3 2020.
  • Funds reported $4.6M of BioLineRX stock for Q4 2020, down 31% quarter-over-quarter.
  • 8 funds opened new BioLineRX positions in Q4 2020 and 5 closed out, a net change of +3 holders.
  • The largest BioLineRX buyer in Q4 2020 was Parkman Healthcare Partners, an estimated $935K added.
  • The largest BioLineRX seller in Q4 2020 was BVF Inc, an estimated $2.77M sold.

Based on aggregated 13F filings for Q4 2020.